A combination of intismeran autogene and Keytruda significantly prolonged recurrence-free survival in melanoma.

The experimental mRNA-based drug sharply reduced the risk of recurrence or death when combined with immunotherapy Keytruda, ...

Moderna’s (MRNA) mRNA-based cancer therapy, intismeran autogene (mRNA-4157), with Merck’s (MRK) anti-PD-1 therapy, Keytruda, ...

Patients with severe melanoma who received the treatment were 49% less likely to die or have their cancer return, ...

The companies have an expansive clinical program for the mRNA neoantigen therapy intismeran autogene in combination with ...

Study subject Remains in Complete Response for 3 YearsExceeds Expectations in Platinum-Resistant Ovarian Cancer Compared to Standard of Care Single-Agent ChemotherapyVancouver, British ...

At five years, KEYTRUDA plus LENVIMA showed a 16.7% overall survival (OS) rate for these patients with mismatch repair proficient (pMMR) advanced endometrial carcinoma versus 7.3% for chemotherapy ...

CytomX Therapeutics is testing CX-801 with Keytruda in a phase 1 trial for metastatic melanoma, focusing on safety and clinical activity. The trial is conducted at UCSF and the University of ...

Keytruda shows consistent efficacy and safety in advanced bladder carcinoma patients ineligible for platinum-based chemotherapy, with varying objective response rates and survival metrics across ...

PADCEV plus KEYTRUDA is the first and only regimen to improve survival when used before and after standard of care (surgical cystectomy) in cisplatin-ineligible patients with muscle-invasive bladder ...

PADCEV plus KEYTRUDA is the first and only regimen to improve survival when used before and after standard of care in cisplatin-ineligible patients with muscle-invasive bladder cancer Results will be ...